Back to top
more

Aurora Cannabis (ACB)

(Delayed Data from NSDQ)

$7.20 USD

7.20
5,790,536

-0.22 (-2.96%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $7.27 +0.07 (0.97%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

How Aurora Cannabis (ACB) Stock Stands Out in a Strong Industry

Aurora Cannabis (ACB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Sweta Killa headshot

Cannabis ETF Tops in May: 5 Stocks That Led The Way

Inside the best performing stocks in the top cannabis ETF of May.

Sanghamitra Saha headshot

How Cannabis ETFs Beat S&P 500 Past Month

Cannabis stocks and ETFs jumped last week. Here's why.

Aurora Cannabis Inc. (ACB) Reports Q3 Loss, Tops Revenue Estimates

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -39.62% and 19.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options

Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.

Aurora Cannabis (ACB) to Report Q3 Earnings: What's in Store?

Aurora Cannabis' (ACB) fiscal third-quarter results likely to reflect solid prospects in the Canadian market.

What's in Store for Ensign Group's (ENSG) Earnings in Q1?

Ensign Group's (ENSG) Q1 results are likely to reflect a better revenue stream.

Sanghamitra Saha headshot

Are Marijuana Stocks, ETFs Poised for Upbeat Earnings?

"Essential Business" status tagged with marijuana selling amid lockdowns should have helped cannabis stocks and ETFs in the first quarter.

Aurora Cannabis Inc (ACB) Expected to Beat Earnings Estimates: Should You Buy?

Aurora Cannabis Inc (ACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardinal Health (CAH) to Report Q3 Earnings: What's in Store?

Cardinal Health's (CAH) fiscal third-quarter performance is likely to reflect solid performance in Pharmaceutical segment.

Trina Mukherjee headshot

3 Medical Product Stocks Set to Beat This Earnings Season

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on several factors.

Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $0.70, marking a -1.55% move from the previous day.

How Hard Will Coronavirus Hit Zimmer Biomet (Zbh) Q1 Earnings?

Zimmer Biomet (ZBH) may have registered improved performances within its Hips and Knees arms due to the nature of the businesses.

What's in the Cards for Quidel (QDEL) This Earnings Season?

Quidel (QDEL) is expected to have gained from its Molecular Diagnostic Solutions business in Q1.

Livongo Health (LVGO) to Post Q1 Earnings: What's in Store?

Livongo Health (LVGO) first-quarter performance to reflect growth in core Livongo for Diabetes solution.

What's in Store for AmerisourceBergen's (ABC) Q2 Earnings?

AmerisourceBergen's (ABC) fiscal second-quarter results likely to reflect solid performance at Pharmaceutical Distribution.

What's in Store for Becton, Dickinson's (BDX) Q2 Earnings?

Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.

OPKO Health (OPK) to Report Q1 Earnings: What's in Store?

OPKO Health's (OPK) first-quarter performance is likely to reflect solid performance from Products and RAYALDEE.

Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings

Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.

What's in the Cards for DaVita (DVA)This Earnings Season?

DaVita (DVA) is expected to have gained from Kidney Care segment in Q1.

What's in Store for Varian Medical (VAR) in Q2 Earnings?

Varian's (VAR) solid Oncology platform is expected to have driven fiscal second-quarter performance.

PerkinElmer (PKI) to Report Q1 Earnings: What's in Store?

PerkinElmer's (PKI) first-quarter results likely to reflect top-line growth and robust performance at Diagnostics segment. However, forex is likely to have remained a woe.

T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?

T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.

Aurora Cannabis Inc. (ACB) Dips More Than Broader Markets: What You Should Know

Aurora Cannabis Inc. (ACB) closed the most recent trading day at $0.75, moving -1.68% from the previous trading session.

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

DENTSPLY SIRONA (XRAY) first-quarter performance to reflect focus on product innovation and R&D.